Skip to main content

Table 3 Logistic regression of possible risk factors and clinical hepatitis

From: Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Risk factors Odd Ratios 95% confidence interval Pvalue
Female gender 1.25 0.21–7.49 0.809
Body weight 1.08 0.98–1.17 0.076
Baseline CD4 cell count 0.99 0.97–1.01 0.352
Receiving anti-tuberculous drugs 7.42 1.27–43.31 0.026
Receiving fluconazole 1.12 0.18–6.90 0.901
Receiving Cotrimoxazole 0.84 0.21–5.44 0.675